Replies to post #318657 on Avid Bioservices Inc (CDMO)

[BioBS2012]

Verified November 2017 by Novartis ( Novartis Pharmaceuticals )

They have PS on the table!


Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS


Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).

https://clinicaltrials.gov/ct2/show/NCT03066648

Yep, certainly vrfies that even those that are targeting PS don't give a FF about $PPHM's BS !! ;-)

Cheers.

[biopharm]

Very nice : ) now Glenn Dranoff sees PS targeting as a value play

All should read:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133725971

CJ posted and proves history of Glenn Dranoff with anti-PS in 2008 and now Novartis picks up Dr Dranoff and they realize they MUST target PS (all working their way to go around PS targeting have failed!!)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37679693

More patents with PS Targeting with Dana Farber
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133747770